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Expanding Access and Method Choice:  
Evidence of Client Self-administration of Injectables and Private Sector 
Provision of Family Planning Services in Three West African Countries
Over the past two decades, the proportion of  all women 
of  reproductive age (15–49 years old) using any form of  
contraception more than doubled in sub-Saharan Africa 
[1]. The demand for family planning (FP) satisfied by a 
modern method increased from 24 percent in 1990 to 52 
percent in 2015, yet about 17 percent of  women still have 
an unmet need for FP [2]. In West Africa, modern con-
traceptive method use remains low with approximately 18 
percent of  all women of  reproductive age using a modern 
method [3]. While in many West African countries FP ser-
vices are offered for free through the public sector, there 
are a number of  reasons people may opt to use the private 
sector for contraceptive supplies. 
Governments across West Africa have expressed their 
commitment to increasing access to voluntary FP through 
global and regional initiatives such as FP2020 and the 
KEY LESSONS
DMPA-SC, including self-injection, and drug shop 
provision of injectable contraceptives were ac-
ceptable and reached new contraceptive users 
as well as young people.
Women received high quality of care through 
new/expanded service delivery channels in 
Ghana and Nigeria.
Job aids and client tools provided ongoing, evi-
dence-based support to providers and clients in 
applying new skills.
Close collaboration with in-country partners and 
stakeholders was crucial to develop contextual-
ized approaches and foster research utilization.
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Ouagadougou Partnership, and through targeted national 
strategies. Ghana, Nigeria and Senegal, among other coun-
tries, have been exploring new strategies to expand access 
to voluntary FP service delivery. Context-specific evidence 
was needed for two promising strategies—1) task sharing 
of  FP services to private sector drug shops and pharmacies 
and 2) introducing self-injection of  subcutaneous depot 
medroxyprogesterone acetate (DMPA-SC). 
The Evidence Project collaborated with stakeholders in 
Ghana, Nigeria, and Senegal to use implementation sci-
ence (IS) to expand the evidence base on these promis-
ing approaches. In this brief, we describe key study results 
from the three countries and how results have been used 
to increase access to voluntary family planning and expand 
method choice.
The Evidence Project explored 
task sharing with drug shops 
and pharmacies as well as self-
administration of injectables 
to improve equitable access to 
voluntary family planning
Previous studies have shown that task sharing contracep-
tive services to private sector drug outlets and including 
self-administered methods in the method mix can improve 
access to voluntary FP services, especially for underserved 
and marginalized populations [4–9]. Task sharing is defined 
as “an expansion of  the levels of  health providers who 
can appropriately deliver health services” [5]. By sharing 
certain tasks across provider types, some benefits of  task 
sharing include increasing access to and availability of  con-
traception and giving higher skilled clinicians more time to 
use their specialized skills or focus on complex tasks [5]. 
Self-administration of  DMPA-SC has the potential to im-
prove access, choice, continuation, and autonomy in coun-
tries that allow women to self-administer DMPA-SC in or 
outside of  a health facility [6,7].
From 2013 to 2019, the Evidence Project collaborated with 
ministries of  health (MOHs) in Ghana, Nigeria, and Sene-
gal to explore ways to improve access to voluntary contra-
ceptive services through task sharing and self-administered 
methods. Figure 1 provides an overview of  the studies 
conducted in Ghana [10],  Nigeria [11,12], Senegal [13–15]. 
Full descriptions of  the study design, results, and IS pro-
cess can be found on the Evidence Project website.
DMPA-SC, including self-injection, 
and drug shop provision of 
injectable contraceptives were 
acceptable and reached new 
contraceptive users as well as young 
people 
In Ghana, 568 women who sought FP services from a pub-
lic health facility and voluntarily chose DMPA-SCi (after 
receiving FP counseling) were interviewed following their 
initial visit and up to two additional times, coinciding with 
iSayana® Press (a registered trademark of Pfizer Inc.) was the brand of 
DMPA-SC used in this study.
OUR IMPLEMENTATION SCIENCE  
APPROACH
The Evidence Project used implementation science 
(IS)—the strategic generation, translation, and use 
of evidence—to strengthen, scale-up, and sustain 
voluntary family planning (FP) services.
Our IS approach was driven by collaboration with 
partners to: (1) define research priorities; (2) imple-
ment research activities; and (3) use evidence for 
decision-making.
This brief is part of a series of briefs synthesizing 
evidence and lessons learned through the project. 
Other briefs include:
• Expanding access to voluntary FP through new 
approaches to workplace interventions
• Innovating and validating measures of complex 
concepts
These briefs and all other Evidence Project publica-
tions can be found at: http://evidenceproject.pop-
council.org/.
DMPA-SC AND TASK SHARING REACHED 
NEW USERS 
• 41% of DMPA-SC clients in Ghana were first-time 
FP users
• 42% of injectable clients in Nigeria began a new 
episode of use at their visit to a PPMV
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their contraceptive follow-up injections. At each injection, 
women were given the option to self-inject DMPA-SC or 
have the provider administer it [10]. Of  the 378 women 
who continued to use DMPA-SC through their third in-
jection, 72 percent chose to self-inject (either at home or 
on-site) while 28 percent chose provider administration. As 
the Ghana Health Service scales up DMPA-SC nationally, 
it will be important for the scale-up program to provide 
women with options for administration modes.
In Nigeria, 561 clients were interviewed within five days 
of  receiving injectable contraceptives from private sector 
Patent and Proprietary Medicine Vendors (PPMVs). For-
ty-two percent of  clients reported starting a new episode 
of  injectable contraceptive use and 61 percent of  all clients 
interviewed had not previously received injectable con-
traceptives from a PPMV. Common reasons for choosing 
PPMVs included convenient location, anonymous care, 
personally knowing the PPMV, and no waiting time [11]. 
Clients also reported high satisfaction with the services 
received by PPMVs and nearly all (99 percent) said they 
would go back to the PPMV for their next injection. These 
results confirm that PPMVs represent an important and 
feasible outlet for increasing access to voluntary FP in Ni-
geria. 
YOUNG PEOPLE FOUND NEW APPROACHES 
AND SOURCES OF FP ACCEPTABLE 
• In Ghana, 33% of DMPA-SC clients were under 24 
(n=185), and 98% of them intended to continue 
using DMPA-SC after their first injection. Among 
young women who chose self-injection at their ini-
tial visit and were still using DMPA-SC six months 
later (n=54), 94% continued to self-inject.
• In Nigeria, 12% of PPMV clients were under 24 
years of age (n=69), and after their first injection, 




41% FP demand satisfied by modern 
methods
Injectables (6%), implants (4%), and 
pills (4%)—most commonly used modern 
methods
STUDY OVERVIEW
• Assessed the feasibility and ac-
ceptability of DMPA-SC self- and/or 
provider-administered injection 
through public sector channels
• Conducted interviews with 1) pro-
viders pre- and post-training and 
2) clients over 6-month period after 
initiating DMPA-SC use 
NIGERIA FP SNAPSHOT
11% mCPR
36% FP demand satisfied by modern 
methods
Implants (3%), male condoms (3%), and 
injectables (2%)—most commonly used 
modern methods
STUDY OVERVIEW
• Assessed the feasibility and accept-
ability of providing injectables by 
trained proprietary medicine vendors 
(PPMVs)
• Conducted multiple interviews with 
1) PPMVs over 9-month period and 
2) clients of PPMVs over 9-month pe-
riod 
FIGURE 1 .  STUDY IMPLEMENTATION SITES*
*Country FP snapshots include data for all women 15–49 years old from the 
latest Demographic and Health Surveys for Ghana (2014), Nigeria (2018), 
and Senegal (2018) [16].
SENEGAL FP SNAPSHOT
18% modern contraceptive prevalence 
rate (mCPR)
55% FP demand satisfied by modern 
methods
Injectables (6%); implants (6%); and 
pills (3%)—most commonly used modern 
methods
STUDY OVERVIEW
Phase 1: Exploratory study
• Explored barriers to and opportunities 
for the provision of voluntary FP by pri-
vate pharmacies
• Conducted literature and legal re-
views, secondary data analysis, and 
key informant interviews
Phase 2: Pilot study
• Trained private pharmacy staff and 
assessed the feasibility of these staff 
to offer counseling, and oral and in-
jectable contraceptives
• Conducted interviews with private 
pharmacies and used mystery clients 
to assess FP counseling skills of staff 
from participating pharmacies
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Before the pilot study in Senegal was initiated, the Evidence 
Project explored opportunities for and barriers to private 
pharmacy provision of  FP services. Through a literature 
review, the Evidence Project found that 43–46 percent 
of  existing private pharmacy clients would be interested 
in directly obtaining oral or injectable contraceptives from 
private pharmacies [14]. Secondary data analysis of  data 
collected by L’Agence pour le Développement du Market-
ing Social (ADEMAS) also found that private pharmacies 
distribute a larger percentage of  short-acting contraceptive 
methods compared to public health facilities [15]. The le-
gal review found that Article 569 from the April 1954 law 
states that “the operation of  a pharmacy is incompatible 
with the practice of  another profession, particularly that 
of  a medical practitioner, a veterinarian, a midwife, or a 
dentist.” This means that while private pharmacies can sell 
condoms and emergency contraceptives over the counter 
and  oral, injectable implant, and IUD contraceptivesii with 
a prescription, they are not permitted to prescribe or ad-
minister contraceptive methods [14].
iiMethods such as the injectable, implant, and IUD may be purchased 
with a prescription but are administered by a qualified heath profes-
sional.
Women received high quality 
services 
Quality of  care in FP includes the interpersonal relations 
and exchange of  information between a provider and a cli-
ent. It can be measured in terms of  quality of  care offered 
by providers through observations of  counseling and mys-
tery clients, and quality of  care received as reported by cli-
ents (typically through client exit interviews). In Ghana and 
Nigeria, client exit interviews were used to capture quality 
of  care received by clients from public sector providers and 
PPMVs. In Senegal, mystery clients were used to observe 
the quality of  care offered by private pharmacies. Figure 2 
shows the proportion of  FP clients in Ghana and Nigeria 
who reported that they received information on seven qual-
ity of  care questions during their initial visit.iii  In Ghana, 
62 percent of  clients reported receiving information on all 
seven components of  quality of  care. For individual ques-
iiiUnder the Evidence Project, Jain et al. [17] validated 22- and 10-item 
measures to assess quality of care received by clients during FP visits 
with providers or frontline health workers. The measures cover four do-
mains of quality of care: respectful care, information exchange about 
method selection, effective use of the selected method, and continuity 
of contraceptive use and care. The study in Nigeria took place before 
these measures were validated and thus the measures are not includ-
ed in this brief but are available here.
FIGURE 2.  CLIENTS’  REPORTS OF QUALIT Y OF CARE RECEIVED IN GHANA AND NIGERIA
Told when to return for follow-up/ 
when next injection is due
Client felt comfortable asking 
questions
Told about other methods
Asked reason for visit
Asked about previous FP/
injectable experience
Told about potential 
side effects of the method
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tions, receipt of  information ranged from 99 percent of  
women who reported that they were told when their next 
injection was due to 79 percent of  women who reported 
that they were told how to manage side effects. These data 
suggest that clients received high quality of  care from the 
public sector providers participating in the Ghana study.  
In Nigeria, 66 percent of  women reported receiving all 
seven components of  quality of  care. Almost all women 
(98%) reported that they were told when to return for their 
next injection. While 91 percent reported that they were 
told about the potential side effects of  their injectable con-
traceptive method, fewer (82%) reported being told how to 
manage those side effects. These results suggest that clients 
enrolled in this study received high quality of  care from 
PPMVs trained in the study in Nigeria. 
In Senegal, 94 percent of  mystery clients observed that 
the pharmacy staff  asked them about their past experience 
with FP, 82 percent were asked if  they had a preferred 
method in mind, and 92 percent discussed other FP meth-
ods with pharmacy staff  (data not shown). However, some 
aspects of  quality of  care were observed less frequently 
such as discussing side effects (33%), warning signs (28%), 
and how to manage the side effects of  the method (24%) 
(data not shown). 
Job aids and client tools provided 
ongoing, evidence-based support to 
providers and clients to help them 
apply new skills
In all three countries, trained providers were equipped with 
relevant job aids and received subsequent supportive su-
pervision and monitoring visits. The results from all three 
country studies suggest that job aids can support providers 
effectively who are new to offering a service and enable cli-
ents to effectively self-administer their contraceptive meth-
od if  they choose.
In Ghana, the Evidence Project used job aids and client 
tools for home and self-injection that were developed by 
PATH. Providers were given a checklist to record the steps 
clients took when practicing DMPA-SC self-injection on 
dummy models. The majority of  providers reported that 
they had memorized the steps of  the checklist and there-
fore did not systematically refer to it when observing clients 
practicing self-injection of  DMPA-SC. For clients who se-
lected home self-injection, women were given self-injection 
instruction sheets and calendars to remind them of  their 
next DMPA-SC injection. Nearly all clients (95%) reported 
using the calendar and most who used it (90%) found it 
very useful.
In Nigeria, job aids supported PPMVs in remember-
ing important, detailed information. The majority of  
PPMVs (86%) reported using the World Health Organiza-
tion’s Medical Eligibility Criteria Wheel, Population Coun-
cil’s Balanced Counseling Strategy Plus cards, and/or FHI 
360 DMPA screening checklist. PPMVs’ reported use of  
job aids was associated with higher levels of  injectable con-
traceptive knowledge nine months after the training [18].  
In the Senegal pilot study, mystery clients observed that in 
nearly three-fourths (73%) of  their visits, the private phar-
macy staff  used a job aid while providing FP counseling. 
Close collaboration with in-country 
partners and stakeholders was 
crucial to develop contextualized 
approaches and foster research 
utilization
In all three countries, the Evidence Project worked close-
ly with key partners and stakeholders, including ministries 
of  health, professional associations, donors and develop-
ment partners, regulatory agencies, nongovernmental or-
ganizations, and private-sector institutions. These close 
and collaborative relationships informed study design and 
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implementation as well as adaptation of  global materialsiv 
and intervention approaches to each country’s context. 
In addition, ongoing stakeholder engagement fostered re-
search utilization and offered opportunities for sustainabil-
ity and scale up.
In Ghana, study implementation was overseen by the Gha-
na Health Service (GHS) and guided by a national tech-
nical advisory group (TAG). This TAG, led by GHS, was 
instrumental in informing the study design; adapting inter-
vention approaches and training materials; and conducting 
monitoring visits to study sites. For instance, based on the 
TAG’s input, concerns about waste management and safe 
disposal practices were incorporated into the study design 
and data collection. 
Study findings were used subsequently by the GHS to in-
form national scale-up plans for DMPA-SC and self-injec-
tion. Research results, for instance, demonstrated the feasi-
bility of  providing clients with a puncture-proof  container 
to store used DMPA-SC devices and instructing them to 
return the container to the facility for final disposal. This 
evidence-informed safe disposal practice was incorporated 
into the national scale-up plans for home self-injection. 
In April 2019, Ghana began expanding access to 
DMPA-SC through service delivery channels in both the 
ivMaterials consulted included the World Health Organization’s Medical 
Eligibility Criteria [19], PATH’s DMPA-SC training curriculum [20, 21], 
FHI 360’s screening checklists for oral and injectable contraceptives 
[22, 23], and the Population Council’s Balanced Counseling Strategy 
Plus [24].
public and private sectors with support from several part-
ners. The GHS used several approaches employed during 
the study for scaling up DMPA-SC, including home self-in-
jection. The GHS replicated and extended the cascade 
training approach used in the study to accelerate national 
scale-up. The same master trainers that were trained for the 
self-injection pilot study went on to then train regional re-
source persons in all 16 administrative regions in the coun-
try using the same job aids, checklists, and client tools that 
were adapted for this study. In addition, the study contrib-
uted evidence to inform national procurement plans and 
routine monitoring of  DMPA-SC services in Ghana. Daily 
logbooks, monthly registers, and health information sys-
tems were recently revised to enable monitoring of  DM-
PA-SC counseling, administration (specifying provider- or 
self-administered), and commodity tracking.
In Nigeria, the Evidence Project worked in partnership 
with the Federal Ministry of  Health (FMOH), state min-
istries of  health from across the country’s geopolitical 
zones, the National Association of   Patent and Proprietary 
Medicines, and several other nongovernmental partners 
in a multi-phased IS approach. This group of  partners in-
formed the study design and development of  FP training 
materials adapted for PPMVs, and participated in study 
monitoring visits. At the design phase, for instance, the 
FMOH co-hosted a stakeholder meeting to garner sup-
port for expanding the study design from only assessing 
PPMVs’ ability to counsel and refer clients for injectable 
contraceptives to also assess PPMVs’ ability to administer 
injectables. Furthermore, a collaborative group of  govern-
ment and nongovernment partners reviewed initial results 
and learning from two states, Oyo and Nasarawa, to refine 
the training curriculum and implementation and data col-
lection plans for four additional states: Bauchi, Cross River, 
Ebonyi, and Cross River.
Evidence from across multiple Nigerian states on the fea-
sibility and acceptability of  PPMV provision of  injectables 
EXPANDED ACCESS TO AND OPTIONS FOR 
DMPA-SC ADMINISTRATION IN GHANA
Evidence generated on the feasibility and accept-
ability of self-injection in Ghana has informed the 
government’s national DMPA-SC scale-up plans, in-
cluding approaches to waste management and safe 
disposal practices.
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was used to expand method choice for women in Nige-
ria. The FMOH and other partners used study results to 
include PPMVs in the national DMPA-SC scale up plans. 
Also, building on the Evidence Project’s work, two addi-
tional states are now piloting PPMV provision of  inject-
ables under another project, supported by the Clinton 
Health Access Initative. In addition, the government con-
tinues to explore formalizing the role of  PPMVs in provid-
ing a range of  voluntary FP methods, including injectables 
and potentially implants, through a tiered accreditation 
system under the IntegratE Project. Partners in Nigeria, 
including the Population Council and others, are currently 
collaborating to pilot this new tiered accreditation system 
to continue to expand method choice through PPMVs and 
community pharmacists. 
In Senegal, the Evidence Project collaborated with champi-
ons within the MOH, national research organizations, and 
professional associations to conduct an exploratory study 
which led to the MOH requesting a follow-up pilot study. 
During the pilot, the Evidence Project continued to work 
with representatives and trainers from the Directorate of  
Maternal and Child Health alongside representatives from 
the Pharmacists Order of  Senegal to adapt the Nigeria 
PPMV training curriculum, in addition to other global and 
local learning materials [19–25], for use with private phar-
macies. The training, for instance, was shortened based 
on guidance from the Pharmacists Order to ensure par-
ticipation from busy private pharmacists. Additional mod-
ifications were also required since the legal framework in 
Senegal restricted services participating pharmacies could 
offer, even with full support from the MOH in collabora-
tion with key stakeholders in the public and private sectors. 
While pharmacists and assistant pharmacists were trained 
on injectable administration and could practice on dummy 
models, they could not provide injectables to interested cli-
ents since pharmacists were not formally linked to a health 
center that could address potential complications. 
Despite the reduced training length for private pharmacy 
staff  in Senegal, absenteeism was common and private 
pharmacists’ consistent participation in the training was 
hampered by their competing business demands. Legal re-
strictions may also have deterred their full participation in 
the training. Additional evidence is needed about how to 
tailor training formats and continued advocacy is needed to 
foster a more favorable legal environment for private phar-
macies to provide a wider range of  contraceptive meth-
ods. Despite these challenges, results of  the study are be-
ing used by the Directorate of  Maternal and Child Health 
and other key partners to advocate for the private sector 
to play a larger role in health service delivery through legal 
and policy changes.
Ways forward
The findings from all three countries demonstrate the po-
tential for increased access to voluntary FP through task 
sharing and self-administration of  injectables.  Additional-
ly, the studies demonstrate the benefit of  using context-re-
sponsive IS to assess feasibility and acceptability of  new 
service delivery options. Provision of  a broad range of  
FP methods through drug shops, pharmacies, and self-ad-
ministration offer important opportunities for women, 
including new users and young people. It is also essential 
to ensure that women receive high-quality care from both 
newly trained providers and existing providers offering 
new services. Ongoing commitment from national govern-
ments and collaboration among a variety of  stakeholders 
will continue to support evidence-informed decisions to 
expand access and method choice.
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